A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden.
Read MoreMed BioGene Inc announced the publication of a study detailing the development and validation of the 15-gene signature used by LungExpress Dx entitled “Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer”.
Read MoreTriLink BioTechnologies inc announced that it has signed a licensing agreement with Biofortuna Ltd. (Biofortuna) for use of CleanAmp dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Read More
Thermo Fisher Scientific
Read MorePCR development company QuantaLife has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections.
Read More